新的美国指南极力推荐对糖尿病更具攻击性的治疗手段
WASHINGTON (Reuters Health) - New diabetes guidelines call for more aggressive goals for diabetes treatment and earlier screening of people at high risk for the disease. The guidelines were released Tuesday by the American College of Endocrinology (ACE) and the American Association of Clinical Endocrinologists (AACE).
At the first-ever ACE Consensus Conference on Guidelines for Glycemic Control, world experts agreed that diabetes screening should begin at age 30, not age 45, in high-risk groups. The prevalence of diabetes has increased 76% among those ages 30 to 39, according to statistics from the US Centers for Disease Control and Prevention.
The guidelines lower the target on the glycosylated hemoglobin A (HbA1c) test to 6.5%. "We have now eliminated any difference between a target level and an action level," Dr. Rhoda Cobin, AACE president, told Reuters Health. Previous guidelines suggested delaying action until an 8% reading.
The consensus panel recommends that the HbA1c test be "universally adopted as the primary method of assessment of glycemic control." It should be performed at least twice a year in patients whose levels are on target and more often in patients whose levels are above target and in those who are changing therapies.
The panel also recommends that the HbA1c test should be called simply the A1C test. "It is critical that patients know their A1C level and their goals," Dr. Claresa Levetan, director of diabetes education at Medstar Clinical Research Center, Washington, DC, said in an ACE/AACE statement.
Finally, the guidelines set targets for plasma glucose: fasting and preprandial levels should be, http://www.100md.com
At the first-ever ACE Consensus Conference on Guidelines for Glycemic Control, world experts agreed that diabetes screening should begin at age 30, not age 45, in high-risk groups. The prevalence of diabetes has increased 76% among those ages 30 to 39, according to statistics from the US Centers for Disease Control and Prevention.
The guidelines lower the target on the glycosylated hemoglobin A (HbA1c) test to 6.5%. "We have now eliminated any difference between a target level and an action level," Dr. Rhoda Cobin, AACE president, told Reuters Health. Previous guidelines suggested delaying action until an 8% reading.
The consensus panel recommends that the HbA1c test be "universally adopted as the primary method of assessment of glycemic control." It should be performed at least twice a year in patients whose levels are on target and more often in patients whose levels are above target and in those who are changing therapies.
The panel also recommends that the HbA1c test should be called simply the A1C test. "It is critical that patients know their A1C level and their goals," Dr. Claresa Levetan, director of diabetes education at Medstar Clinical Research Center, Washington, DC, said in an ACE/AACE statement.
Finally, the guidelines set targets for plasma glucose: fasting and preprandial levels should be, http://www.100md.com